Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry.

ABSTRACT:

Aims

The introduction of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care-Describing European Heart Failure Management (ARIADNE) registry will evaluate patient characteristics, practice patterns, outcomes, and healthcare resource utilization in the outpatient setting across Europe, with the main focus on factors that guide physicians' decisions to start and continue sacubitril/valsartan in patients with HFrEF.

Methods and results

ARIADNE, a prospective, observational registry will enrol 9000 ambulatory patients with HFrEF in 23 European countries Supplement 1. The study will describe 4500 patient

SUBMITTER: Zeymer U 

PROVIDER: S-EPMC7160498 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature